@article{ref1,
title="Pharmacotherapeutic study of efficacy, safety and prognostic analysis of anti snake venom serum in snake bite patients",
journal="International journal of basic and clinical pharmacology",
year="2017",
author="Inamdar, Khalid and Parhate, Sudhakar M. and Randad, Rahul D.",
volume="6",
number="4",
pages="906-912",
abstract="BACKGROUND: Snakebite is a common medical emergency especially in the rural areas. The effective measure to treat most of the manifestations of venomous snake bite is timely administration of anti-snake venom serum (ASVS). Problems associated with ASVS use are lack of evidence for optimal dose schedule and occurrence of hypersensitivity reactions.<br><br>METHODS: A retrospective review of snakebite cases was carried out from record section of a tertiary care teaching hospital from January 2011 to December 2011.<br><br>RESULTS: Out of total 202 snakebite patients admitted during the study period, age group of 21-30 years (mainly male victims) accounted for highest no. of snakebite cases (25.7%). The mean (±SD) dose of ASVS used was 124 (±112) mL. 11.8% patients had suffered from adverse drug reactions due to ASVS. 7.4% patients required mechanical ventilation. Overall mortality in our study was 9.4%. Mortality was higher (50%) where the time interval between the snakebite and initiation of treatment was >6 hours. Out of total 15 patients who required mechanical ventilation, n=10 (66.6%) patient died.<br><br>CONCLUSIONS: In our study, mean dose of ASVS used was as per WHO guidelines. Less incidence of adverse drug reaction due to ASVS may be because of co-administration of corticosteroids and anti-histaminics. Delay in getting treatment with ASVS, neurotoxic envenomation and respiratory failure, were the risk factors associated with adverse prognosis due to snake bite in our set up.<p /> <p>Language: en</p>",
language="en",
issn="2319-2003",
doi="10.18203/2319-2003.ijbcp20171102",
url="http://dx.doi.org/10.18203/2319-2003.ijbcp20171102"
}